Akebia Therapeutics, Inc.
AKBA · XNASCIK 1517022fmd_0MMKASNA1G3MPHMBQNFA86KZMHManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Sep 30, 2026, 56 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 2 | 181 | 208 | 335 | 295 | 212 | 292 | 195 | 160 | 236 |
| Net interest income | – | – | – | – | – | – | – | – | – | – |
| Cost of revenue | – | – | 8 | 145 | 296 | 151 | 86 | 74 | 63 | 39 |
| Gross profit | – | – | 200 | 190 | (2) | 61 | 207 | 120 | 97 | 197 |
| Research and development | 116 | 231 | 291 | 323 | 218 | 148 | 130 | 63 | 38 | 62 |
| Selling, general and administrative | 22 | 27 | 87 | 149 | 154 | 174 | 139 | 100 | 107 | 107 |
| Total operating expenses | 138 | 258 | 378 | 476 | 376 | 325 | 288 | 167 | 147 | 173 |
| Operating income | (136) | (77) | (178) | (286) | (378) | (265) | (81) | (46) | (50) | 23 |
| Interest and investment income | 1 | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (0) | 0 | 0 | (1) | 2 | 2 | 3 | 1 | 0 | 0 |
| Income before taxes | (136) | (74) | (172) | (286) | (385) | (282) | (94) | (52) | (69) | (4) |
| Income tax expense | – | – | (28) | (7) | 0 | 0 | 0 | 0 | 0 | 2 |
| Net income from continuing operations | – | – | (144) | (280) | (385) | (282) | (94) | (52) | (69) | (5) |
| Net income | (136) | (74) | (144) | (280) | (385) | (282) | (94) | (52) | (69) | (5) |
| Net income to common shareholders | (136) | – | – | – | – | – | – | – | – | – |